Halozyme Therapeutics, Inc. (HALO)

Market Cap	8.07B
Revenue (ttm)	1.18B
Net Income (ttm)	557.28M
Shares Out	116.97M
EPS (ttm)	4.37
PE Ratio	15.80
Forward PE	9.91
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,657,050
Open	71.75
Previous Close	71.69
Day's Range	68.04 - 71.84
52-Week Range	42.01 - 79.50
Beta	1.16
Analysts	Buy
Price Target	73.40 (+6.41%)
Earnings Date	Oct 30, 2025

About HALO

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States and internationally. The company’s products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the disper...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1998
• Employees: 350
• Stock Exchange: NASDAQ
• Ticker Symbol: HALO
• Website: https://halozyme.com

Financial Performance

In 2024, Halozyme Therapeutics's revenue was $1.02 billion, an increase of 22.44% compared to the previous year's $829.25 million. Earnings were $444.09 million, an increase of 57.71%.

Analyst Summary

According to 10 analysts, the average rating for HALO stock is "Buy." The 12-month stock price target is $73.4, which is an increase of 6.41% from the latest price.

Price Target

$73.4

(6.41% upside)

Analyst Consensus: Buy